Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants

被引:47
作者
Erickson-Ridout, Kathryn Kelly [1 ]
Zhu, Junjia [2 ]
Lazarus, Philip [1 ,2 ,3 ]
机构
[1] Penn State Coll Med, Dept Pharmacol, Hershey, PA 17033 USA
[2] Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA 17033 USA
[3] Penn State Canc Inst, Mol Epidemiol & Canc Control Program, Hershey, PA USA
关键词
metabolism; olanzapine; UDP-glucuronosyltransferases; UGT1A4; UGT2B10; variant alleles; HUMAN UDP-GLUCURONOSYLTRANSFERASES; ANTIPSYCHOTIC AGENT OLANZAPINE; WEIGHT-GAIN; HUMAN LIVER; NICOTINE GLUCURONIDATION; ATYPICAL ANTIPSYCHOTICS; PLASMA-CONCENTRATIONS; BODY-WEIGHT; SCHIZOPHRENIA; PHARMACOKINETICS;
D O I
10.1097/FPC.0b013e328348c76b
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives Olanzapine is an antipsychotic used in the treatment of schizophrenia, bipolar disorder, and treatment-resistant depression. Glucuronidation by the UDP-glucuronosyltransferase (UGT) family of enzymes is the major mode of olanzapine metabolism, and polymorphisms in these enzymes could contribute to interindividual variability in olanzapine metabolism and therapeutic response. Methods Cell lines overexpressing individual UGT enzymes were used to determine which UGTs have enzymatic activity against olanzapine, characterize the kinetics of this reaction, and examine the effects of UGT variants on olanzapine metabolism. A bank of 105 human liver microsomes (HLM) were used to perform a phenotype-genotype study comparing glucuronidation activity against UGT genotype. Results Cell lines overexpressing the individual UGTs 1A4 and 2B10 exhibited glucuronidation activity against olanzapine. The UGT1A4(24Pro/48Val) variant exhibited a 3.7-fold (P<0.0001) higher V-max/K-M for the formation of the olanzapine-10-N-glucuronide isomer 1, and a 4.3-fold (P<0.0001) higher V-max/K-M for the formation of the olanzapine-10-N-glucuronide isomer 2 than wild-type UGT1A4(24Pro/48Leu). The UGT2B10(67Y) variant exhibited no glucuronidation activity against olanzapine. In a screening of 105 HLM specimens, there was a 2.1-fold (P = 0.04) and 1.6-fold (P = 0.0017) increase in the rate of olanzapine-10-N-glucuronide isomer 1 and olanzapine-4'-N-glucuronide formation, and a 2-fold (P = 0.02) increase in the overall olanzapine glucuronidation formation, in HLM with the UGT1A4 ((star)3/(star)3)/UGT2B10 ((star)1/(star)1) genotype compared with HLM with the UGT1A4 ((star)1/(star)1)/UGT2B10 ((star)1/(star)1) genotype. There was a 1.9-fold (P<0.003) decrease in the formation of both isomers of the olanzapine-10-N-glucuronide, a 2.7-fold (P<0.0001) decrease in olanzapine-4'-N-glucuronide formation, and a 2.1-fold (P = 0.0002) decrease in the overall olanzapine glucuronide formation in HLM with at least one UGT2B10(star)2 allele. In regression analysis, the UGT1A4(star)3 (P<0.02) and UGT2B10(star)2 (P<0.002) alleles were significant predictors of the formation of all olanzapine glucuronide isomers. Conclusion The UGTs 1A4 and 2B10 glucuronidate olanzapine and functional variants of these UGTs significantly alter olanzapine glucuronidation in vitro. These data suggest that the UGT1A4(star)3 and UGT2B10(star)2 alleles contribute significantly to interindividual variability in olanzapine metabolism. Pharmacogenetics and Genomics 21:539-551 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:539 / 551
页数:13
相关论文
共 56 条
[1]   Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents [J].
Albaugh, Vance L. ;
Henry, Cathy R. ;
Bello, Nicholas T. ;
Hajnal, Andras ;
Lynch, Susan L. ;
Halle, Beth ;
Lynch, Christopher J. .
OBESITY, 2006, 14 (01) :36-51
[2]  
[Anonymous], 2000, Am J Psychiatry, V157, P1
[3]  
Baldessarini RJ TF., 2001, Drugs and the treatment of psychiatric disorders, V10th
[4]   Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? [J].
Baptista, T ;
Beaulieu, S .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2002, 47 (08) :742-749
[5]   UGT2B10 Genotype Influences Nicotine Glucuronidation, Oxidation, and Consumption [J].
Berg, Jeannette Zinggeler ;
von Weymarn, Linda B. ;
Thompson, Elizabeth A. ;
Wickham, Katherine M. ;
Weisensel, Natalie A. ;
Hatsukami, Dorothy K. ;
Murphy, Sharon E. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (06) :1423-1431
[6]   Nicotine Metabolism in African Americans and European Americans: Variation in Glucuronidation by Ethnicity and UGT2B10 Haplotype [J].
Berg, Jeannette Zinggeler ;
Mason, Jesse ;
Boettcher, Angela J. ;
Hatsukami, Dorothy K. ;
Murphy, Sharon E. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 332 (01) :202-209
[7]  
Bergemann N, 2004, PHARMACOPSYCHIATRY, V37, P63
[8]   Functional Significance of UDP-Glucuronosyltransferase Variants in the Metabolism of Active Tamoxifen Metabolites [J].
Blevins-Primeau, Andrea S. ;
Sun, Dongxiao ;
Chen, Gang ;
Sharma, Arun K. ;
Gallagher, Carla J. ;
Amin, Shantu ;
Lazarus, Philip .
CANCER RESEARCH, 2009, 69 (05) :1892-1900
[9]   Antipsychotics and the risk of diabetes: a general data review [J].
Bottai, A ;
Quintin, P ;
Perrin, E .
EUROPEAN PSYCHIATRY, 2005, 20 :S349-S357
[10]   Olanzapine - Pharmacokinetic and pharmacodynamic profile [J].
Callaghan, JT ;
Bergstrom, RF ;
Ptak, LR ;
Beasley, CM .
CLINICAL PHARMACOKINETICS, 1999, 37 (03) :177-193